Our Mission

Empowering the oncology community to improve quality of care and patient outcomes through transformational data analytics.

Conquering Cancer Through Research, Education, and Promotion of the Highest Quality Patient Care

The mission of the American Society of Clinical Oncology (ASCO) drives its numerous initiatives, and CancerLinQ is one of our most ambitious. This program was created to give oncologists a robust quality monitoring system that collects and analyzes data from all patient encounters. But it also gives us the ability to learn from every one of them so that we can deliver to our patients the highest possible quality of care.

We continue to promote and provide for lifelong learning for oncology professionals, and we will always support cancer research. But CancerLinQ allows us to build on our global network of oncology expertise so that we can make a tangible difference in the lives of people with cancer.

CancerLinQ LLC is a subsidiary of the American Society of Clinical Oncology established for the development and operation of the CancerLinQ initiative. CancerLinQ is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. The team is comprised of staff focused solely on CancerLinQ-a team dedicated to using big data to help conquer cancer. CancerLinQ LLC has two offices-the main office collocated with located in ASCO headquarters in Alexandria, VA and a second office in San Francisco, CA.

Our Vision

Shaping the future of cancer care through data-driven innovation.

CancerLinQ™ is a system that continually learns from itself and enables change:

  • Tracks the quality of care in real time to ensure patients get all the care they need and none they don’t
  • Gains insights from de-identified data on thousands of patients, potentially identifying important trends and increasing the confidence of care decisions
  • Visualizes patients’ medical histories in powerful new ways
Shoppers have Amazon. Students have Google. Oncologists will have CancerLinQ.

Meet Our Leadership and Advisory Committees

CancerLinQ Board of Governors
Clifford A. Hudis, MD, FACP, FASCO, CEO, Chair
Allen Lichter, MD, FASCO, Past ASCO CEO
Aaron Sasson
GT Nexus, Inc.
Greg Parekh, PhD
New Rhein Healthcare
Peter Paul Yu, MD, FASCO
Hartford Healthcare Cancer Institute
Ronald Andrews
Thermo Fisher Scientific Inc.
Craig R. Nichols headshot
Craig R. Nichols, MD, FACP
Intermountain Healthcare
CancerLinQ Leadership Team
Kevin Fitzpatrick, Chief Executive Officer
Robert Miller, MD, FASCO, FACP, Medical Director
Linda Jensen, Chief Financial Officer
Anil Nair, Chief Technology Officer
Andrew Stewart, Chief of Oncology Data
Jennifer Wong, Chief of Strategic Alliances
Alaap Shah, Sr Counsel, Chief Privacy & Security Officer
Carmen Jackson, Chief of Staff
David Dornstreich, Chief, Corporate Engagement
George Komatsoulis PhD, Chief of Bio-Informatics
CancerLinQ Physician Advisory Committee
Keith Thompson MD, Chair
Montgomery Cancer Center
Douglas W. Blayney, MD, FASCO
Stanford University
Elizabeth M. Blanchard, MD
Southcoast Centers for Cancer Care
Jose A. Bufill MD, FASCP
Michiana Hematology-Oncology, PC
Paolo F. Caimi, MD
Case Comprehensive Cancer Center
John Deeken, MD
INOVA Comprehensive Cancer and Research Institute, Falls Church, Va.
Dax Kurbegov, MD
Catholic Health Initiative
Eric Martin, MD
Medical Oncology Hematology Consultants
Jamal Misleh, MD
Medical Oncology Hematology Consultants
John Niederhuber, MD
Michiana Hematology-Oncology, serving several communities in Indiana
Ritwick Panicker MD, MBBS, FACP, MRCP
Cancer Treatment Centers of America
David J. Perry, MD
Washington Hospital Center
Amitabha Sarma, MD
Virginia Cancer Specialists
Anna Schorer, MD
Member HIT Workgroup Liaison
Mark E. Thompson, MD
The Mark H. Zangmeister Cancer Center
Tracey F. Weisberg, MD
New England Cancer Specialist
Allison Zibelli, MD
Jefferson Kimmel Cancer Center
Solomon Zimm, MD
Space Coast Cancer Center
CancerLinQ Patient Advisory Committee
Elda Railey, Chair
Research Advocacy Network
Karen Durham
Susan G. Komen
Florence Kurttila
Fight Colorectal Cancer
Jim L. Omel, MD
Education and Advocacy
Joan Tashbar
Research Advocacy Network
Jack Whelan
Jack Whelan Inc
CancerLinQ Data Governance Oversight Committee
Donald Trump, MD, Chair
Inova Dwight and Martha Schar Cancer Institute
James L. Abbruzzese, MD, FASCO, Vice-Chair
Duke University
Angela R. Bradbury, MD
Hospital of the University of Pennsylvania
Reshma Jagsi, MD, DPhil
University of Michigan
Dana E. Rollison, PhD
Moffitt Cancer Center
Deborah Schrag, MD, MPH, FASCO
Dana-Farber Cancer Institute
Peter Paul Yu, MD, FASCO
Hartford Healthcare Cancer Institute
Robin Zon, MD, FACP, FASCO
Michiana Hematology Oncology
Funda Meric-Bernstam, MD
MD Anderson
CancerLinQ Data Analytics Committee
Gregory Hess, MD,MBA, MSc, Chair
Symphony Health Solutions
Anthony Bower, PhD
Bower Research Group
Lynne Penberthy, MD, MPH
National Cancer Institute
Anne-Marie Meyer, PhD
University of North Carolina at Chapel Hill
Sheikh Usman Iqbal, MD, MPH, MBA
Jeremy Warner, MD, MS
Vanderbilt University Medical Center
Kathleen Foley, PhD
Discovery Research & Publications Committee
Gary Lyman, MD, Chair
Fred Hutch
Dawn Hershman, MD, Vice-Chair
Jamie Holloway, PhD
Broad Institute/Cure Forward
Sandra Wong, MD
Dax Kurbegov, MD
Amy Lin, MD
Sean Khozin, MD, MPH
Kerin Adelson, MD
Jeff Kirshner, MD
Private Practice
Karla Ballman, PhD

Why We Care

Having been in the oncology arena for numerous years, it is clear that many oncologists don't have the resources or time to keep up with the ever changing oncology landscape from various perspectives which can impact the quality of care they provide or could provide to their patients, including cancer patients that are in my family. CancerLinQ is a solution that enables any type of provider, both large and small, to improve the quality of care they deliver on a daily basis that not only benefits them individually, but most importantly the ability to affect patient outcomes (such as those in my family) with every day real world evidence where survival is not a given, nor is it a choice in many situations.

-Jeff Szykowny, External Relations

CancerLinQ Is Well On Its Way